Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
-- On track to complete rolling NDA submission to the FDA for setmelanotide in POMC and LEPR deficiency obesities in the first quarter of 2020 -- -- Granted orphan drug designation by the European Medicines Agency for setmelanotide in Alström syndrome -- …